What it is

Selank is a synthetic peptide described as an analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide fragment. Selank has been studied primarily in Russian and Eastern European research contexts for anxiolytic-like and stress-related effects in preclinical models, and it is discussed as a nootropic/anxiolytic peptide in gray-market settings.

Selank is not FDA-approved.

Why people use it

Non-medical use focuses on anxiety, stress resilience, and cognitive clarity. These uses are largely based on limited clinical translation and a preclinical literature that does not establish effectiveness for common anxiety disorders under modern trial standards.

History and origin

Selank’s concept builds from tuftsin biology and the broader search for peptide-based neuroactive compounds that might modulate stress responses with fewer sedating effects than benzodiazepines. Much of the published work is preclinical, with ongoing interest in molecular and gene-expression effects.

How it works

Mechanistic proposals include modulation of GABAergic signaling and downstream stress-response pathways, with reported changes in gene expression related to neurotransmission in cellular and animal models. These findings are hypothesis-generating; they do not establish that the same pathways are meaningfully and safely modulated in humans at real-world exposures.

Evidence landscape

The evidence base is dominated by animal studies, cellular experiments, and narrative mechanistic reviews. There is a relative scarcity of large, well-controlled randomized trials in widely diagnosed anxiety disorders published in the mainstream clinical literature, limiting confidence in real-world effectiveness.

Safety reality

Because selank is not regulated as an approved medicine in the U.S., safety data are incomplete. Key practical risks include unknown long-term effects, variability in product identity, and contamination. Even if a peptide appears non-sedating, it can still have meaningful CNS effects that interact with psychiatric conditions or medications.

References

Comparison of anxiolytic effect and tolerability of selank and phenazepam in anxiety disorders (2014). https://pubmed.ncbi.nlm.nih.gov/25176261/

Efficacy and possible mechanisms of action of selank in generalized anxiety (2008). https://pubmed.ncbi.nlm.nih.gov/18454096/

Optimization of treatment of anxiety disorders with selank (2015). https://pubmed.ncbi.nlm.nih.gov/26356395/